Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2

Technology appraisal guidance
Reference number: TA257
Published: 27 June 2012

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Royal College of Physicians (joint NCRI, RCR, ACP)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Royal College of Physicians (joint NCRI, RCR, ACP)

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Royal College of Physicians (joint NCRI, RCR, ACP)
27 April 2012
(234.13 Kb 8 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 25 April 2012